Menu Search
Equities

Charmacy Pharmaceutical Co Ltd

2289:HKG.HZ

Charmacy Pharmaceutical Co Ltd

Actions
  • Price (HKD)9.80
  • Today's Change0.50 / 5.38%
  • Shares traded7.00k
  • 1 Year change-24.62%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Charmacy Pharmaceutical Co Ltd had net income fall -43.25% from 90.47m to 51.34m despite a 5.47% increase in revenues from 4.18bn to 4.40bn. An increase in the selling, general and administrative costs as a percentage of sales from 3.19% to 3.22% was a component in the falling net income despite rising revenues.
Gross margin6.91%
Net profit margin1.15%
Operating margin1.60%
Return on assets1.70%
Return on equity8.88%
Return on investment8.48%
More ▼

Cash flow in CNYView more

In 2023, Charmacy Pharmaceutical Co Ltd increased its cash reserves by 63.99%, or 44.07m. Cash Flow from Financing totalled 101.26m or 2.30% of revenues. In addition the company used 96.54m for operations while cash from investing totalled 39.34m.
Cash flow per share0.8093
Price/Cash flow per share11.49
Book value per share5.90
Tangible book value per share5.10
More ▼

Balance sheet in CNYView more

Charmacy Pharmaceutical Co Ltd has a Debt to Total Capital ratio of 58.82%, a higher figure than the previous year's 2.41%.
Current ratio1.07
Quick ratio0.7714
Total debt/total equity1.43
Total debt/total capital0.5882
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)3.39%
Div growth rate (5 year)0.00%
Payout ratio (TTM)0.00%
EPS growth(5 years)2.48
EPS (TTM) vs
TTM 1 year ago		-46.20
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.